The pathogenesis and diagnosis of acute kidney injury in multiple myeloma

Nature Reviews Nephrology

Volumn 8, Issue 1, 2012, Pages 43-51

  Hutchison, Colin A ^a   Batuman, Vecihi ^b   Behrens, Judith ^c   Bridoux, Frank ^d   Sirac, Christophe ^e   Dispenzieri, Angela ^f   Herrera, Guillermo A ^g   Lachmann, Helen ^h   Sanders, Paul W ⁱ  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST HELIER HOSPITAL   (United Kingdom)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f MAYO CLINIC   (United States)

^g BOSTWICK LABORATORIES   (United States)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CUBILIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; INTERLEUKIN 8; MEGALIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PARAPROTEIN; TAMM HORSFALL GLYCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE KIDNEY FAILURE; APOPTOSIS; ATROPHY; BLOOD EXAMINATION; BRUSH BORDER VESICLE; CYTOKINE PRODUCTION; ENDOCYTOSIS; EPITHELIAL MESENCHYMAL TRANSITION; FANCONI RENOTUBULAR SYNDROME; GENE SILENCING; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; MULTIPLE MYELOMA; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CELL DYSCRASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ELECTROPHORESIS; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RENAL PROTECTION; REVIEW; URINALYSIS;

ACUTE KIDNEY INJURY; HUMANS; MULTIPLE MYELOMA;

EID: 84455205655     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.168     Document Type: Review

References (107)

1. Peto, R. Factors of prognostic significance in myelomatosis. J. Clin. Pathol. 25, 555 (1972).
2. Haynes, R. J., Read, S., Collins, G. P., Darby, S. C. & Winearls, C. G. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol. Dial. Transplant. 25, 419-426 (2010).
3. Bladé, J. et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch. Intern. Med. 158, 1889-1893 (1998). (Pubitemid 28440861)
4. Leung, N. et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 73, 1282-1288 (2008). (Pubitemid 351693147)
5. Hutchison, C.-A. et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin. J. Am. Soc. Nephrol. 4, 745-754 (2009).
6. Hutchison, C. A. et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J. Am. Soc. Nephrol. 22, 1129-1136 (2011).
7. Arimura, A., Li, M. & Batuman, V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107, 661-668 (2006). (Pubitemid 43076392)
8. Batuman, V., Dreisbach, A. W. & Cyran, J. Light-chain binding sites on renal brush-border membranes. Am. J. Physiol. 258, F1259-F1265 (1990). (Pubitemid 20185262)
9. Batuman, V. & Guan, S. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am. J. Physiol. 272, F521-F530 (1997).
10. Batuman, V., Guan, S., O'Donovan, R. & Puschett, J. B. Effect of myeloma light chains on phosphate and glucose transport in renal proximal tubule cells. Ren. Physiol. Biochem. 17, 294-300 (1994). (Pubitemid 24329521)
11. Batuman, V., Sastrasinh, M. & Sastrasinh, S. Light chain effects on alanine and glucose uptake by renal brush border membranes. Kidney Int. 30, 662-665 (1986).
12. Batuman, V. et al. Myeloma light chains are ligands for cubilin (gp280). Am. J. Physiol. 275, F246-F254 (1998).
13. Klassen, R. B., Allen, P. L., Batuman, V., Crenshaw, K. & Hammond, T. G. Light chains are a ligand for megalin. J. Appl. Physiol. 98, 257-263 (2005). (Pubitemid 40041255)
14. Li, M., Balamuthusamy, S., Simon, E. E. & Batuman, V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am. J. Physiol. Renal Physiol. 295, F82-F90 (2008).
15. Li, M., Hering-Smith, K. S., Simon, E. E. & Batuman, V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol. Dial. Transplant. 23, 860-870 (2008). (Pubitemid 351767551)
16. Pote, A., Zwizinski, C., Simon, E. E., Meleg-Smith, S. & Batuman, V. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am. J. Kidney Dis. 36, 735-744 (2000).
17. Sengul, S., Zwizinski, C. & Batuman, V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am. J. Physiol. Renal Physiol. 284, F1245-F1254 (2003). (Pubitemid 36578452)
18. Sengul, S. et al. Endocytosis of light chains induces cytokines through activation of NF-κB in human proximal tubule cells. Kidney Int. 62, 1977-1988 (2002). (Pubitemid 35366153)
19. Sanders, P. W., Herrera, G. A., Chen, A., Booker, B. B. & Galla, J. H. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J. Clin. Invest. 82, 2086-2096 (1988). (Pubitemid 19054958)
20. Sanders, P. W., Booker, B. B., Bishop, J. B. & Cheung, H. C. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J. Clin. Invest. 85, 570-576 (1990). (Pubitemid 20070067)
21. Sanders, P. W., Herrera, G. A., Kirk, K. A., Old, C. W. & Galla, J. H. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab. Invest. 64, 527-537 (1991).
22. Sanders, P. W. & Booker, B. B. Pathobiology of cast nephropathy from human Bence Jones proteins. J. Clin. Invest. 89, 630-639 (1992).
23. Huang, Z. Q., Kirk, K. A., Connelly, K. G. & Sanders, P. W. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J. Clin. Invest. 92, 2975-2983 (1993). (Pubitemid 24006568)
24. Sanders, P. W. & Herrera, G. A. Monoclonal immunoglobulin light chain-related renal diseases. Semin. Nephrol. 13, 324-341 (1993). (Pubitemid 23144164)
25. Huang, Z. Q. & Sanders, P. W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J. Clin. Invest. 99, 732-736 (1997). (Pubitemid 27097676)
26. Ying, W. Z. & Sanders, P. W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am. J. Pathol. 158, 1859-1866 (2001). (Pubitemid 32422951)
27. Herrera, G. A. & Sanders, P. W. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib. Nephrol. 153, 105-115 (2007). (Pubitemid 44836017)
28. Wang, P. X. & Sanders, P. W. Immunoglobulin light chains generate hydrogen peroxide. J. Am. Soc. Nephrol. 18, 1239-1245 (2007). (Pubitemid 46536910)
29. Basnayake, K., Ying, W. Z., Wang, P. X. & Sanders, P. W. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J. Am. Soc. Nephrol. 21, 1165-1173 (2010).
30. Ying, W. Z., Wang, P. X., Aaron, K. J., Basnayake, K. & Sanders, P. W. Immunoglobulin light chains activate NF-κB in renal epithelial cells through a Src-dependent mechanism. Blood 117, 1301-1307 (2011).
31. Holland, M. D., Galla, J. H., Sanders, P. W. & Luke, R. G. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int. 27, 46-50 (1985). (Pubitemid 15130684)
32. Huang, Z. Q. & Sanders, P. W. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab. Invest. 73, 810-817 (1995). (Pubitemid 26002340)
33. Solomon, A., Weiss, D. T. & Kattine, A. A. Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845-1851 (1991).
34. Bence Jones, H. Papers on clinical pathology. Lancet 50, 88-92 (1847).
35. Berggård, I. & Peterson, P. A. Polymeric forms of free normal κ and a; chains of human immunoglobulin. J. Biol. Chem. 244, 4299-4307 (1969).
36. Mead, G. P. et al. Serum free light chains for monitoring multiple myeloma. Br. J. Haematol. 126, 348-354 (2004). (Pubitemid 39005714)
37. Markowitz, G. S. Dysproteinemia and the kidney. Adv. Anat. Pathol. 11, 49-63 (2004).
38. Sanders, P. W., Herrera, G. A. & Galla, J. H. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 32, 851-861 (1987). (Pubitemid 18015516)
39. Galla, J. H., Herrera, G. A. & Sanders, P. W. Differential toxicity of human Bence-Jones proteins in the rat proximal convoluted tubule in vivo. Contrib. Nephrol. 68, 198-202 (1988).
40. Sanders, P. W., Herrera, G. A., Lott, R. L. & Galla, J. H. Morphologic alterations of the proximal tubules in light chain-related renal disease. Kidney Int. 33, 881-889 (1988).
41. Guan, S., el-Dahr, S., Dipp, S. & Batuman, V. Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J. Investig. Med. 47, 496-501 (1999). (Pubitemid 129537122)
42. Batuman, V. Proximal tubular injury in myeloma. Contrib. Nephrol. 153, 87-104 (2007). (Pubitemid 44836016)
43. Sengul, S., Li, M. & Batuman, V. Myeloma kidney: toward its prevention-with new insights from in vitro and in vivo models of renal injury. J. Nephrol. 22, 17-28 (2009).
44. Khan, A. M. et al. Myeloma light chain-induced renal injury in mice. Nephron Exp. Nephrol. 116, e32-e41 (2010).
45. Maldonado, J. E. et al. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am. J. Med. 58, 354-364 (1975).
46. Herlitz, L. C., Roglieri, J., Resta, R., Bhagat, G. & Markowitz, G. S. Light chain proximal tubulopathy. Kidney Int. 76, 792-797 (2009).
47. Weiss, J. H. et al. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int. 20, 198-210 (1981). (Pubitemid 11004878)
48. Tanner, G. A. & Knopp, L. C. Glomerular blood flow after single nephron obstruction in the rat kidney. Am. J. Physiol. 250, F77-F85 (1986).
49. Tanner, G. A. & Evan, A. P. Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int. 36, 1050-1060 (1989). (Pubitemid 20049212)
50. Start, D. A., Silva, F. G., Davis, L. D., D'Agati, V. & Pirani, C. L. Myeloma cast nephropathy: immunohistochemical and lectin studies. Mod. Pathol. 1, 336-347 (1988).
51. Ying, W. Z. & Sanders, P. W. Dietary salt regulates expression of Tamm-Horsfall glycoprotein in rats. Kidney Int. 54, 1150-1156 (1998). (Pubitemid 28449901)
52. Woodruff, R. & Sweet, B. Multiple myeloma with massive Bence Jones proteinuria and preservation of renal function. Aust. NZ J. Med. 7, 60-62 (1977). (Pubitemid 8080976)
53. Khamlichi, A. A. et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 86, 3655-3659 (1995).
54. Decourt, C. et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 94, 3559-3566 (1999). (Pubitemid 29536152)
55. Sirac, C. et al. Role of the monoclonal κ chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 108, 536-543 (2006). (Pubitemid 44061353)
56. Myatt, E. A. et al. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc. Natl Acad. Sci. USA 91, 3034-3038 (1994). (Pubitemid 24130169)
57. Aucouturier, P. et al. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. J. Immunol. 150, 3561-3568 (1993). (Pubitemid 23129737)
58. Rocca, A. et al. Sequences of V kappa L subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome. J. Immunol. 155, 3245-3252 (1995).
59. Messiaen, T. et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 79, 135-154 (2000). (Pubitemid 30327529)
60. Déret, S. et al. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng. 12, 363-369 (1999). (Pubitemid 29209948)
61. L germ line gene use and clonal plasma cell burden. Blood 98, 714-720 (2001).
62. Denoroy, L., Déret, S. & Aucouturier, P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol. Lett. 42, 63-66 (1994).
63. Cogné, M., Preud'homme, J. L., Bauwens, M., Touchard, G. & Aucouturier, P. Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. J. Clin. Invest. 87, 2186-2190 (1991).
64. Stevens, F. J. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7, 200-211 (2000).
65. Enqvist, S., Sletten, K., Stevens, F. J., Hellman, U. & Westermark, P. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE 2, e981 (2007).
66. Déret, S. et al. Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. Protein Eng. 10, 1191-1197 (1997). (Pubitemid 28046179)
67. del Pozo Yauner, L. et al. Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains. Proteins 72, 684-692 (2008). (Pubitemid 351928522)
68. Stevens, P. W. et al. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci. 4, 421-432 (1995).
69. Kaplan, B. et al. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br. J. Haematol. 144, 705-715 (2009).
70. Kaplan, B., Livneh, A. & Gallo, G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br. J. Haematol. 136, 723-728 (2007).
71. Klimtchuk, E. S. et al. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry 49, 9848-9857 (2010).
72. Yamamoto, K. et al. The amyloid fibrils of the constant domain of immunoglobulin light chain. FEBS Lett. 584, 3348-3353 (2010).
73. Keeling, J., Teng, J. & Herrera, G. A. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab. Invest. 84, 1322-1338 (2004). (Pubitemid 40063697)
74. Basnayake, K. et al. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J. Clin. Pathol. 63, 884-887 (2010).
75. Bradwell, A. R. et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47, 673-680 (2001). (Pubitemid 32275810)
76. Hutchison, C. A. et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 9, 11 (2008).
77. Katzmann, J. A. et al. Serum reference intervals and diagnostic ranges for free κ and free a; immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin. Chem. 48, 1437-1444 (2002). (Pubitemid 34925779)
78. Hutchison, C. A., Basnayake, K. & Cockwell, P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat. Rev. Nephrol. 5, 621-628 (2009).
79. Katzmann, J. A. et al. Screening panels for detection of monoclonal gammopathies. Clin. Chem. 55, 1517-1522 (2009).
80. Durie, B. G. et al. on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 20, 1467-1473 (2006). (Pubitemid 44264086)
81. Dispenzieri, A. et al. on behalf of the International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23, 215-224 (2009).
82. Hutchison, C. A. et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1684-1690 (2008).
83. Herrera, G. A. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch. Pathol. Lab. Med. 133, 249-267 (2009).
84. Herrera, G. A. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann. Diagn. Pathol. 4, 174-200 (2000). (Pubitemid 30480217)
85. Korbet, S. M. & Schwartz, M. M. Multiple myeloma. J. Am. Soc. Nephrol. 17, 2533-2545 (2006). (Pubitemid 44300969)
86. Herrera, G. A. & Picken, M. M. in Heptinstall's Pathology of the Kidney (eds Jennette, J. C., Olson, J. L. & Schwartz, M. M.) 853-910 (Lippincott-Raven, Philadelphia, 2006).
87. Herrera, G. A. in Silva's Diagnostic Renal Pathology (eds Zhou, X. J., Laszik, Z., Nadasdy, T., D'Agati, V. D. & Silva, F.) 345-406 (Cambridge University Press, Cambridge, 2009).
88. Kapur, U., Barton, K., Fresco, R., Leehey, D. J. & Picken, M. M. Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch. Pathol. Lab. Med. 131, 1368-1372 (2007). (Pubitemid 47427590)
89. Leung, N. et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am. J. Kidney Dis. 43, 147-153 (2004). (Pubitemid 38049446)
90. Short, A. K., O'Donoghue, D. J., Riad, H. N., Short, C. D. & Roberts, I. S. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am. J. Nephrol. 21, 237-240 (2001). (Pubitemid 32620202)
91. Gu, X. & Herrera, G. A. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch. Pathol. Lab. Med. 130, 165-169 (2006). (Pubitemid 43237983)
92. Isaac, J. & Herrera, G. A. Cast nephropathy in a case of Waldenström's macroglobulinemia. Nephron 91, 512-515 (2002). (Pubitemid 34765257)
93. Herrera, G. A. The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions. Med. Electron Microsc. 34, 1-18 (2001).
94. Herrera, G. A. & Turbat-Herrera, E. A. Ultrastructural immunolabeling in the diagnosis of monoclonal light-and heavy-chain-related renal diseases. Ultrastruct. Pathol. 34, 161-173 (2010).
95. Picken, M. M. & Herrera, G. A. The burden of "sticky" amyloid: typing challenges. Arch. Pathol. Lab. Med. 131, 850-851 (2007). (Pubitemid 46906375)
96. Sethi, S. et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin. J. Am. Soc. Nephrol. 5, 2180-2187 (2010).
97. Montseny, J. J. et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol. Dial. Transplant. 13, 1438-1445 (1998).
98. Komatsuda, A. et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am. J. Kidney Dis. 35, E9 (2000).
99. Hotta, O. & Taguma, Y. Resolution of nodular glomerular lesions in a patient with light-chain nephropathy. Nephron 91, 504-505 (2002). (Pubitemid 34765254)
100. Clark, A. D., Shetty, A. & Soutar, R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 13, 79-90 (1999). (Pubitemid 29286913)
101. Haubitz, M. & Peest, D. Myeloma-new approaches to combined nephrological-haematological management. Nephrol. Dial. Transplant. 21, 582-590 (2006). (Pubitemid 43372902)
102. Penfield, J. G. Multiple myeloma in end-stage renal disease. Semin. Dial. 19, 329-334 (2006). (Pubitemid 44091709)
103. Mead, G. P. & Drayson, M. T. Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients. Blood 114, 1717 (2009).
104. Drayson, M. et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 108, 2013-2019 (2006). (Pubitemid 44395015)
105. Cockwell, P. & Hutchison, C. A. Management options for cast nephropathy in multiple myeloma. Curr. Opin. Nephrol. Hypertens. 19, 550-555 (2010).
106. Pratt, G. The evolving use of serum free light chain assays in haematology. Br. J. Haematol. 141, 413-422 (2008). (Pubitemid 351550561)
107. Elliss-Brookes, L. et al. Routes to Diagnosis: NCIN Data Briefing. National Cancer Intelligence Network online, http://www.ncin.org.uk/ publications/data-briefings/routes-to-diagnosis.aspx (2010).